In one of the largest reviews to date of SMARCA4-mutated overall survival data in NSCLC, two consistent trends emerged from the twenty-one publications in scope: First, SMARCA4 NSCLC mutated patients had statistically worse OS than SMARCA4 WT patients. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.